23andMe Study Identifies Genetic Variants Affecting Obesity Drug Efficacy and Side Effects
A study conducted by the research arm of genetic testing company 23andMe has identified genetic variations that influence the effectiveness and side effects of GLP-1 agonist-based weight-loss drugs. The study analyzed the genomes of nearly 28,000 users of these drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Researchers found a missense variant in the GLP1R gene associated with greater weight loss and multiple variants in the GIPR gene linked to increased susceptibility to side effects like nausea and vomiting. These findings, published in the journal Nature, suggest that genetic testing could help tailor weight-loss treatments to individual patients, enhancing efficacy and safety. 
